Find Iptacopan Hydrochloride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Lnp023, 1644670-37-0, Lnp-023, Iptacopan [inn], Iptacopan [usan], Nvp-lnp023-nx
Molecular Formula
C25H30N2O4
Molecular Weight
422.5  g/mol
InChI Key
RENRQMCACQEWFC-UGKGYDQZSA-N
FDA UNII
8E05T07Z6W

Iptacopan Hydrochloride
Iptacopan is an orally available, small-molecule inhibitor of complement factor B (FB) with potential immunomodulatory activity. Upon administration, iptacopan binds to FB and prevents the formation of the alternative pathway (AP) C3-convertase (C3bBb). This limits the cleavage of C3 to the active fragment C3b and may prevent C3b-mediated extravascular hemolysis in certain complement-driven disorders such as paroxysmal nocturnal hemoglobinuria (PNH).
1 2D Structure

Iptacopan Hydrochloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid
2.1.2 InChI
InChI=1S/C25H30N2O4/c1-4-31-19-10-12-27(22(14-19)17-5-7-18(8-6-17)25(28)29)15-21-20-9-11-26-24(20)16(2)13-23(21)30-3/h5-9,11,13,19,22,26H,4,10,12,14-15H2,1-3H3,(H,28,29)/t19-,22-/m0/s1
2.1.3 InChI Key
RENRQMCACQEWFC-UGKGYDQZSA-N
2.1.4 Canonical SMILES
CCOC1CCN(C(C1)C2=CC=C(C=C2)C(=O)O)CC3=C(C=C(C4=C3C=CN4)C)OC
2.1.5 Isomeric SMILES
CCO[C@H]1CCN([C@@H](C1)C2=CC=C(C=C2)C(=O)O)CC3=C(C=C(C4=C3C=CN4)C)OC
2.2 Other Identifiers
2.2.1 UNII
8E05T07Z6W
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Lnp023

2. 1644670-37-0

3. Lnp-023

4. Iptacopan [inn]

5. Iptacopan [usan]

6. Nvp-lnp023-nx

7. Nvp-lnp023

8. 8e05t07z6w

9. 4-[(2s,4s)-4-ethoxy-1-[(5-methoxy-7-methyl-1h-indol-4-yl)methyl]piperidin-2-yl]benzoic Acid

10. 4-[(2~{s},4~{s})-4-ethoxy-1-[(5-methoxy-7-methyl-1~{h}-indol-4-yl)methyl]piperidin-2-yl]benzoic Acid

11. Benzoic Acid, 4-((2s,4s)-4-ethoxy-1-((5-methoxy-7-methyl-1h-indol-4-yl)methyl)-2-piperidinyl)-

12. Benzoic Acid, 4-[(2s,4s)-4-ethoxy-1-[(5-methoxy-7-methyl-1h-indol-4-yl)methyl]-2-piperidinyl]-

13. Iptacopan [who-dd]

14. Unii-8e05t07z6w

15. Chembl4594448

16. Schembl16400416

17. Gtpl10710

18. Us9682968, Example-26a

19. Bdbm160475

20. Ex-a5728

21. Who 11259

22. Zinc223246892

23. At30389

24. Compound 41 [pmid: 32073845]

25. Hy-127105

26. Cs-0093107

27. A935227

28. 4-((2s,4s)-(4-ethoxy-1-((5-methoxy-7-methyl-1h-indol-4-yl)methyl)piperidin-2-yl))benzoic Acid

29. 4-((2s,4s)-4-ethoxy-1-((5-methoxy-7-methyl-1h-indol-4-yl)methyl)piperidin-2-yl)benzoicacid

30. Jgq

2.4 Create Date
2015-02-16
3 Chemical and Physical Properties
Molecular Weight 422.5 g/mol
Molecular Formula C25H30N2O4
XLogP31.8
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count7
Exact Mass422.22055744 g/mol
Monoisotopic Mass422.22055744 g/mol
Topological Polar Surface Area74.8 Ų
Heavy Atom Count31
Formal Charge0
Complexity594
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

NDC API

read-more
read-more

01

PharmaVenue
Not Confirmed
arrow
arrow
PharmaVenue
Not Confirmed

IPTACOPAN HYDROCHLORIDE

NDC Package Code : 44139-0100

Start Marketing Date : 2023-12-05

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients withC3 glomerulopathy.


Lead Product(s): Iptacopan Hydrochloride

Therapeutic Area: Nephrology Brand Name: Fabhalta

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 26, 2024

blank

01

PharmaVenue
Not Confirmed
PharmaVenue
Not Confirmed

Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients withC3 glomerulopathy.

Brand Name : Fabhalta

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 26, 2024

blank

Details:

Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is approved for the treatment of patients with IgA nephropathy (IgAN).


Lead Product(s): Iptacopan Hydrochloride

Therapeutic Area: Nephrology Brand Name: Fabhalta

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 08, 2024

blank

02

PharmaVenue
Not Confirmed
PharmaVenue
Not Confirmed

Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is approved for the treatment of patients with IgA nephropathy (IgAN).

Brand Name : Fabhalta

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 08, 2024

blank

Details:

Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients with IgA nephropathy (IgAN).


Lead Product(s): Iptacopan Hydrochloride

Therapeutic Area: Nephrology Brand Name: Fabhalta

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 15, 2024

blank

03

PharmaVenue
Not Confirmed
PharmaVenue
Not Confirmed

Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients with IgA nephropathy (IgAN).

Brand Name : Fabhalta

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 15, 2024

blank

Details:

Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia.


Lead Product(s): Iptacopan Hydrochloride

Therapeutic Area: Rare Diseases and Disorders Brand Name: Fabhalta

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 22, 2024

blank

04

PharmaVenue
Not Confirmed
PharmaVenue
Not Confirmed

Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia.

Brand Name : Fabhalta

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 22, 2024

blank

Details:

LNP023 (iptacopan), an oral, Factor B inhibitor of the alternative complement pathway being developed in Phase 3 for patients with C3 glomerulopathy, which met its primary endpoint by providing clinically meaningful and statistically significant proteinuria reduction.


Lead Product(s): Iptacopan Hydrochloride

Therapeutic Area: Nephrology Brand Name: LNP023

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 11, 2023

blank

05

PharmaVenue
Not Confirmed
PharmaVenue
Not Confirmed

Details : LNP023 (iptacopan), an oral, Factor B inhibitor of the alternative complement pathway being developed in Phase 3 for patients with C3 glomerulopathy, which met its primary endpoint by providing clinically meaningful and statistically significant proteinu...

Brand Name : LNP023

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 11, 2023

blank

Details:

FDA approved Fabhalta® (iptacopan), a Factor B inhibitor of the alternative complement pathway 15-17, as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria.


Lead Product(s): Iptacopan Hydrochloride

Therapeutic Area: Rare Diseases and Disorders Brand Name: Fabhalta

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 05, 2023

blank

06

PharmaVenue
Not Confirmed
PharmaVenue
Not Confirmed

Details : FDA approved Fabhalta® (iptacopan), a Factor B inhibitor of the alternative complement pathway 15-17, as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

Brand Name : Fabhalta

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 05, 2023

blank

Details:

LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysis in PNH.


Lead Product(s): Iptacopan Hydrochloride

Therapeutic Area: Nephrology Brand Name: LNP023

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 02, 2023

blank

07

PharmaVenue
Not Confirmed
PharmaVenue
Not Confirmed

Details : LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysi...

Brand Name : LNP023

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 02, 2023

blank

Details:

LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysis in PNH.


Lead Product(s): Iptacopan Hydrochloride

Therapeutic Area: Rare Diseases and Disorders Brand Name: LNP023

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 26, 2023

blank

08

PharmaVenue
Not Confirmed
PharmaVenue
Not Confirmed

Details : LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysi...

Brand Name : LNP023

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 26, 2023

blank

Details:

LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysis in PNH.


Lead Product(s): Iptacopan Hydrochloride

Therapeutic Area: Rare Diseases and Disorders Brand Name: LNP023

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 13, 2022

blank

09

PharmaVenue
Not Confirmed
PharmaVenue
Not Confirmed

Details : LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysi...

Brand Name : LNP023

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 13, 2022

blank

Details:

LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysis in PNH.


Lead Product(s): Iptacopan Hydrochloride

Therapeutic Area: Rare Diseases and Disorders Brand Name: LNP023

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 08, 2022

blank

10

PharmaVenue
Not Confirmed
PharmaVenue
Not Confirmed

Details : LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysi...

Brand Name : LNP023

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 08, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

PharmaVenue
Not Confirmed
arrow
arrow
PharmaVenue
Not Confirmed

IPTACOPAN HYDROCHLORIDE

Brand Name : FABHALTA

Dosage Form : CAPSULE;ORAL

Dosage Strength : EQ 200MG BASE

Packaging :

Approval Date : 2023-12-05

Application Number : 218276

Regulatory Info : RX

Registration Country : USA

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

NOVARTIS

Switzerland
PharmaVenue
Not Confirmed
arrow

NOVARTIS

Switzerland
arrow
PharmaVenue
Not Confirmed

IPTACOPAN HYDROCHLORIDE

Brand Name : FABHALTA

Dosage Form : CAPSULE;ORAL

Dosage Strength : EQ 200MG BASE

Approval Date : 2023-12-05

Application Number : 218276

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
FDA approvals slump 19% in H1 2024; NASH, COPD, PAH get new treatment options
The first half of 2024 saw a significant slowdown in approvals of new drugs and biologics by the US Food and Drug Administration (FDA) compared to the same period last year.FDA’s Center for Drug Evaluation and Research (CDER) approved 21 drugs in H1 2024, reflecting a 19 percent decrease from the 26 approvals granted in H1 2023.  Of them, 81 percent (17) were first-in-class drugs (therapies that use a new and unique mechanism of action), while small molecules made up for 67 percent (14) of the total drugs approved.Similarly, the Center for Biologics Evaluation and Research (CBER) granted approvals to only eight biologics, as compared to 10 in H1 2023.Health Canada also saw a drop in drug approvals as only 10 drugs were okayed in H1 2024, as opposed to 13 approvals in H1 2023.The European Medicines Agency (EMA) saw a marginal rise in drug authorizations at 15 for H1 2024 as compared to 14 approvals in H1 2023. Interestingly, the EMA also saw a surge in pending decisions (applications under review) — from two in H1 2023 to 14 in H1 2024.View New Drug Approvals in H1 2024 with Estimated Sales (Free Excel Available)Merck, Madrigal, Verona bag approvals for breakthrough meds; Lilly’s donanemab okayedThe first half saw some closely watched drugs win regulatory approvals. FDA approved a breakthrough therapy from Merck — Winrevair (sotatercept) — that treats adults with hypertension caused by the constriction of arteries in the lungs, known as pulmonary arterial hypertension (PAH).Merck had acquired Winrevair through its US$ 11.5 billion acquisition of Acceleron Pharma in 2021. The therapy is set to generate nearly US$ 3 billion in global peak sales by 2028. Another breakthrough therapy approved in H1 2024 is Madrigal’s Rezdiffra (resmetirom), the first FDA-approved treatment for adults with the common fatty liver disease — nonalcoholic steatohepatitis (NASH). Rezdiffra is expected to touch sales of US$ 2.1 billion by 2028.The agency also approved the first maintenance treatment for chronic obstructive pulmonary disease (COPD) in over 20 years — Verona’s Ohtuvayre. The drug has a novel mechanism of action and is the first inhaled maintenance treatment for COPD. Approved in June by the FDA, Ohtuvayre is forecast to bring in global sales of US$ 1.5 billion by 2030.The approval of Eli Lilly’s donanemab was surprisingly delayed, and finally came through on July 2 after an FDA advisory committee voted unanimously in favor of its benefits outweighing its risks. To be sold as  Kinsula, the Alzheimer's drug is estimated to bring in US$ 2.2 billion in sales by 2028.Across the pond, EMA approved Novo Nordisk’s weekly insulin injection Awiqli (insulin icodec). The replacement insulin in Awiqli acts in the same way as the body’s own insulin and helps glucose enter cells from the blood. Meanwhile, FDA rejected this once-a-week insulin earlier this month and has requested information related to the manufacturing process.View New Drug Approvals in H1 2024 with Estimated Sales (Free Excel Available) ImmunityBio, Geron, Day One win approvals for their oncology drugsIn what marks the first approval for ImmunityBio, FDA greenlit Anktiva (nogapendekin alfa inbakicept-pmln) as part of a combination therapy to treat a type of bladder cancer. Anktiva is a next-generation immunotherapy that creates long-term immunity by activating the so-called natural killer (NK) cells and T-cells. It will compete with Merck’s Keytruda. Anktiva’s yearly sales by 2030 are expected to be around US$ 1.7 billion.BeiGene’s PD-1 blocker Tevimbra (tislelizumab) got the go-ahead from the FDA as the treatment for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. Tevimbra’s 2028 global sales are forecast to bring in US$ 1.6 billion.FDA signed off on Geron’s Rytelo (imetelstat) for treating transfusion-dependent anemia in patients with low- to intermediate-risk myelodysplastic syndromes (MDS), a group of blood cancers. This was Geron’s maiden approval and Rytelo is expected to bring in US$ 1.3 billion by 2030.Day One Biopharmaceuticals’ Ojemda (tovorafenib) was granted FDA’s accelerated approval to treat certain types of pediatric brain cancer. This is the first FDA approval of a systemic therapy for treating what is the most common form of childhood brain tumor, including fusions. Ojemda is forecast to bring in US$ 1 billion in sales by 2030.FDA granted accelerated approval to Amgen’s Imdelltra (tarlatamab-dlle) for adults in advanced stages of small cell lung cancer (SCLC) that has proven to be hard to treat or has worsened despite platinum-based chemotherapy. Imdelltra is expected to bring in annual sales of US$ 975 million by 2030.View New Drug Approvals in H1 2024 with Estimated Sales (Free Excel Available) Infectious disease drugs from Basilea, Merck, rare disease med from Ipsen bag  approvalsAfter oncology, infections and infectious diseases, and rare diseases were the two therapeutic areas that saw the second and third most approvals, respectively. FDA approved Basilea Pharmaceutica’s Zevtera (ceftobiprole medocaril sodium for injection), an antibiotic for bacterial infections including multidrug-resistant strains.The US agency also approved Merck’s next-generation vaccine designed to protect adults from pneumococcus bacteria that causes serious illnesses and pneumonia. The jab, known as Capvaxive, helped produce an immune response against all 21 variations (serotypes) of the bacteria that it targeted. These 21 strains account for about 85 percent of invasive pneumococcal disease cases in adults aged 65 and above. FDA also approved Moderna’s mRESVIA, a messenger RNA-based (mRNA) respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by the syncytial virus. This is the first non-Covid mRNA vaccine to be approved in the US.The agency granted accelerated approval to Ipsen’s Iqirvo (elafibranor) to treat primary biliary cholangitis (PBC), a rare liver disease. This is the first new medicine approved in nearly a decade for the treatment of PBC. Orchard Therapeutics’ Lenmeldy secured FDA approval to become the first gene therapy in the US for a rare pediatric disorder, known as metachromatic leukodystrophy (MLD). The debilitating hereditary disease affects the brain and the nervous system and causes loss of cognitive and motor functions and early death.View New Drug Approvals in H1 2024 with Estimated Sales (Free Excel Available) Our viewThe increased momentum of drug approvals witnessed after the pandemic appears to have slowed down, but what’s encouraging is the increase in first-in-class therapies, cancer drugs and promising new treatment options for a range of conditions such as PAH, NASH, and COPD.The second half has already kicked off with the approval of Lilly’s donanemab. And there are several pathbreaking drugs likely to be approved soon, such as Karuna Therapeutics’ schizophrenia drug KarXT and BridgeBio’s heart drug acoramidis. There is every possibility that new drug approvals will spring back up in H2 2024. 

Impressions: 2145

https://www.pharmacompass.com/radio-compass-blog/fda-approvals-slump-19-in-h1-2024-nash-copd-pah-get-new-treatment-options

#PharmaFlow by PHARMACOMPASS
25 Jul 2024

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
PharmaVenue
Not Confirmed

NOVARTIS

Switzerland
arrow
PharmaVenue
Not Confirmed

IPTACOPAN HYDROCHLORIDE

US Patent Number : 11951101

Drug Substance Claim :

Drug Product Claim :

Application Number : 218276

Patent Use Code : U-3895

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2041-07-15

blank

02

arrow
PharmaVenue
Not Confirmed

NOVARTIS

Switzerland
arrow
PharmaVenue
Not Confirmed

IPTACOPAN HYDROCHLORIDE

US Patent Number : 11723901

Drug Substance Claim :

Drug Product Claim :

Application Number : 218276

Patent Use Code : U-3980

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2038-08-30

blank

03

arrow
PharmaVenue
Not Confirmed

NOVARTIS

Switzerland
arrow
PharmaVenue
Not Confirmed

IPTACOPAN HYDROCHLORIDE

US Patent Number : 10093663

Drug Substance Claim :

Drug Product Claim :

Application Number : 218276

Patent Use Code : U-3980

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-07-14

blank

04

arrow
PharmaVenue
Not Confirmed

NOVARTIS

Switzerland
arrow
PharmaVenue
Not Confirmed

IPTACOPAN HYDROCHLORIDE

US Patent Number : 9682968

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 218276

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-07-14

blank

05

arrow
PharmaVenue
Not Confirmed

NOVARTIS

Switzerland
arrow
PharmaVenue
Not Confirmed

IPTACOPAN HYDROCHLORIDE

US Patent Number : 11603363

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 218276

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2041-05-25

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

read-more
read-more

01

arrow
PharmaVenue
Not Confirmed

NOVARTIS

Switzerland
arrow
PharmaVenue
Not Confirmed

IPTACOPAN HYDROCHLORIDE

Exclusivity Code : NCE

Exclusivity Expiration Date : 2028-12-05

Application Number : 218276

Product Number : 1

Exclusivity Details :

blank

02

arrow
PharmaVenue
Not Confirmed

NOVARTIS

Switzerland
arrow
PharmaVenue
Not Confirmed

IPTACOPAN HYDROCHLORIDE

Exclusivity Code : ODE-456

Exclusivity Expiration Date : 2030-12-05

Application Number : 218276

Product Number : 1

Exclusivity Details :

blank

03

arrow
PharmaVenue
Not Confirmed

NOVARTIS

Switzerland
arrow
PharmaVenue
Not Confirmed

IPTACOPAN HYDROCHLORIDE

Exclusivity Code : I-949

Exclusivity Expiration Date : 2027-08-07

Application Number : 218276

Product Number : 1

Exclusivity Details :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Iptacopan Manufacturers

A Iptacopan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Iptacopan, including repackagers and relabelers. The FDA regulates Iptacopan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Iptacopan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Iptacopan Suppliers

A Iptacopan supplier is an individual or a company that provides Iptacopan active pharmaceutical ingredient (API) or Iptacopan finished formulations upon request. The Iptacopan suppliers may include Iptacopan API manufacturers, exporters, distributors and traders.

Iptacopan NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Iptacopan as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Iptacopan API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Iptacopan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Iptacopan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Iptacopan NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Iptacopan suppliers with NDC on PharmaCompass.

Iptacopan GMP

Iptacopan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Iptacopan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Iptacopan GMP manufacturer or Iptacopan GMP API supplier for your needs.

Iptacopan CoA

A Iptacopan CoA (Certificate of Analysis) is a formal document that attests to Iptacopan's compliance with Iptacopan specifications and serves as a tool for batch-level quality control.

Iptacopan CoA mostly includes findings from lab analyses of a specific batch. For each Iptacopan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Iptacopan may be tested according to a variety of international standards, such as European Pharmacopoeia (Iptacopan EP), Iptacopan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Iptacopan USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty